Let's Accelerate
a Novel Therapeutic
for COVID-19
AVEX Impact is the nonprofit arm of AEVOLVE AG, a project designed to accelerate the pace of innovation in the health space. AVEX Impact was designed to nurture a spirit of community, participation, and purpose—to further the objectives and reach of AEVOLVE AG’s supported technologies.
As the COVID-19 pandemic continues to deepen its effect on the world’s health and economic climate, the AVEX Impact as a nonprofit organization is playing a major role in ensuring that the innovations in health technology are within reach of those who need it most, instituting programs of relevance that benefit both promising COVID-19 medical solutions and patients.
AVEX Impact is the nonprofit arm of AEVOLVE AG, a project designed to accelerate the pace of innovation in the health space. AVEX Impact was designed to nurture a spirit of community, participation, and purpose—to further the objectives and reach of AEVOLVE AG’s supported technologies.
AVEX Impact was designed to nurture a spirit of community,
AEVOLVE SUPPORTS NUCISION
NuCISION’s technology proposes a new antiviral model that opens up a new approach towards beating the virus. It is developing a novel cell-penetrating programmable enzyme-based anti-viral model to directly address SARS-CoV-2.
This new medical technology, which is a departure from antibody or vaccine approaches, is expected to enter human trials by Q4 2020.
It is developing a novel cell-penetrating programmable enzyme-based anti-viral model to directly address SARS-CoV-2.
Learn more about: